Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 6,939.9 | 6,827.3 | 6,127.5 | 7,982.2 | 7,932.9 | 7,803.3 | 7,668.4 | 5,997.8 |
| Revenue growth | 1.6% | 11.4% | -23.2% | 0.6% | 1.7% | 1.8% | 27.9% | 28.3% |
| Cost of goods sold | 2,019.5 | 1,960.4 | 1,824.3 | 2,252.6 | 2,271.9 | 2,132.9 | 2,381.8 | 1,800.6 |
| Gross profit | 4,920.4 | 4,866.9 | 4,303.2 | 5,729.6 | 5,661.0 | 5,670.4 | 5,286.6 | 4,197.2 |
| Gross margin | 70.9% | 71.3% | 70.2% | 71.8% | 71.4% | 72.7% | 68.9% | 70.0% |
| Selling, general and administrative | 698.8 | 452.1 | 825.8 | 3,343.8 | 3,379.3 | 3,104.7 | 2,944.6 | 2,284.2 |
| Research and development | 406.0 | 435.8 | 322.8 | 449.3 | 391.7 | 369.9 | 365.6 | 268.8 |
| EBITA | 1,384.8 | 1,263.8 | 1,103.0 | 1,791.9 | 1,609.4 | 1,734.7 | 1,418.1 | -34.8 |
| EBITA margin | 20.0% | 18.5% | 18.0% | 22.4% | 20.3% | 22.2% | 18.5% | -0.6% |
| Amortization of intangibles | 526.8 | 529.5 | 512.1 | 584.3 | 595.9 | 603.9 | 565.9 | 337.4 |
| EBIT | 858.0 | 734.3 | 590.9 | 1,207.6 | 1,013.5 | 1,130.8 | 852.2 | -372.2 |
| EBIT margin | 12.4% | 10.8% | 9.6% | 15.1% | 12.8% | 14.5% | 11.1% | -6.2% |
| Pre-tax income | 403.5 | 499.0 | -105.2 | 905.8 | -271.1 | 464.6 | 399.6 | 153.2 |
| Income taxes | 112.3 | 53.5 | -96.0 | -225.7 | 108.2 | -1,348.8 | 95.0 | 7.0 |
| Tax rate | 27.8% | 10.7% | 91.3% | | | | 23.8% | 4.6% |
| Earnings from continuing ops | 290.2 | 445.0 | -10.7 | 1,131.6 | -379.2 | 1,813.8 | 305.9 | 147.0 |
| Earnings from discontinued ops | -58.8 | -43.4 | -128.2 | | | | | |
| Net income | 231.4 | 401.6 | -138.9 | 1,131.6 | -379.2 | 1,813.8 | 305.9 | 147.0 |
| Net margin | 3.3% | 5.9% | -2.3% | 14.2% | -4.8% | 23.2% | 4.0% | 2.5% |
| |
| Diluted EPS | $1.38 | $2.12 | ($0.05) | $5.47 | ($1.86) | $8.90 | $1.51 | $0.77 |
| Shares outstanding (diluted) | 210.3 | 210.4 | 207.0 | 206.7 | 203.5 | 203.7 | 202.4 | 189.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|